Inventor · disambiguated record
Yuetian Yan
Also filed as: YAN YUETIAN
15 granted patents·20 pending applications·14 citations·filing 2007–2025
89Inventor score
Top patents by PatentIndex Score
35 records- 0196US11899023B2Quantitation and identification of dimers in co-formulationsREGENERON PHARMA·Filed 2022·Granted Feb 13, 2024·2 cites·8 claims
- 0296US11536725B2Quantitation and identification of dimers in co-formulationsREGENERON PHARMA·Filed 2020·Granted Dec 27, 2022·4 cites·9 claims
- 0394US12000811B2Method and system of identifying and quantifying antibody fragmentationREGENERON PHARMA·Filed 2022·Granted Jun 4, 2024·1 cites·21 claims
- 0489US11385239B2Method and system of identifying and quantifying a proteinREGENERON PHARMA·Filed 2019·Granted Jul 12, 2022·2 cites·20 claims
- 0588US12320790B2Method and system of identifying and quantifying antibody fragmentationREGENERON PHARMA·Filed 2024·Granted Jun 3, 2025·0 cites·20 claims
- 0688US10718754B2System and method for characterizing protein dimerizationREGENERON PHARMA·Filed 2019·Granted Jul 21, 2020·2 cites·22 claims
- 0786US12399182B2Quantitation and identification of dimers in co-formulationsREGENERON PHARMA·Filed 2023·Granted Aug 26, 2025·0 cites·28 claims
- 0886US11525833B2Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysisREGENERON PHARMA·Filed 2020·Granted Dec 13, 2022·1 cites·25 claims
- 0985US12169204B2Coupled native mass spectrometry for antibody analysisREGENERON PHARMA·Filed 2023·Granted Dec 17, 2024·0 cites·15 claims
- 1084US11525823B2System and method for characterizing protein dimerizationREGENERON PHARMA·Filed 2020·Granted Dec 13, 2022·1 cites·30 claims
- 1183US11486864B2Method and system of identifying and quantifying antibody fragmentationREGENERAN PHARMACEUTICALS INC·Filed 2020·Granted Nov 1, 2022·1 cites·18 claims
- 1282US11885811B2Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysisREGENERON PHARMA·Filed 2022·Granted Jan 30, 2024·0 cites·13 claims
- 1381US2023314446A1Method and system of identifying and quantifying a proteinREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1480US12174173B2System and method for characterizing protein dimerizationREGENERON PHARMA·Filed 2022·Granted Dec 24, 2024·0 cites·26 claims
- 1580US11714092B2Method and system of identifying and quantifying a proteinREGENERON PHARMA·Filed 2022·Granted Aug 1, 2023·0 cites·20 claims
- 1678US2025206803A1Methods of characterizing and purifying vegf receptor fusion proteinREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1775US2023266286A1Platform for Native Liquid Chromatography-Mass SpectrometryREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1871US11598756B2Platform for native liquid chromatography-mass spectrometryREGENERON PHARMA·Filed 2021·Granted Mar 7, 2023·0 cites·20 claims
- 1966US2024248097A1Mass spectrometry-based characterization of antibodies co-expressed in vivoREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2065US2023348533A1Bioanalysis of therapeutic antibodies and related products using immunoprecipitation and native sec-pcd-ms detectionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2161US2024255518A1Characterization of serine-lysine cross-link in antibody high molecular weight speciesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2260US2024255519A1Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysisREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2360US2023084196A1Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologicREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2460US2023017454A1Bioanalysis of therapeutic antibodies and related products using immunoprecipitation and native scx-ms detectionREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2560US2023077710A1HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINSREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2659US2025264478A1Identification and quantitation of heterodimers in mab therapeuticsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2759US2024036056A1Mass spectrometry-based strategy for determining product-related variants of a biologicREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2858US2023375565A1Mass spectrometry-based strategy for determining product-related variants of a biologicREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2957US2023002445A1Coupling isoelectric focusing-based fractionation with mass spectrometry analysisREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3057US2025244299A1Characterization of binding-related cqas in thereapeutic mabsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3156US2021382067A1High-throughput and mass-spectrometry-based method for quantitating antibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3253US2023045769A1Mass spectrometry-based strategy for determining product-related variants of a biologicREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3352US2025250628A1Methods of identifying and/or characterizing a polynucleotide of interestREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3450US2008066933A1Rotary fire sprinklerYAN YUETIAN·Filed 2007·Application pending·0 cites
- 3549US2023032322A1Mass spectrometry-based strategy for determining product-related variants of a biologicREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yuetian Yan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →